de Oliveira Lucia Helena, Danovaro-Holliday M Carolina, Matus Cuauhtemoc Ruiz, Andrus Jon Kim
Immunization Unit, Family and Community Health, Pan American Health Organization, 525 23rd Street, NW, Washington, DC 20037, USA.
Expert Rev Vaccines. 2008 Apr;7(3):345-53. doi: 10.1586/14760584.7.3.345.
In Latin America and the Caribbean, rotavirus causes approximately 15,000 deaths, 75,000 hospitalizations, 2 million clinic visits and 10 million cases of rotavirus diarrhea annually. Two safe vaccines are available that are effective in preventing severe illness. To date, seven countries in Latin America (Brazil, Ecuador, El Salvador, Panama, Mexico, Nicaragua and Venezuela) have introduced the vaccine. For successful rotavirus vaccine introduction, the lessons learned re-emphasize the critical need for countries to have precise plans that will ensure technical, programmatic and financial sustainability of vaccine introduction. Of these lessons learned, programmatic feasibility and financial sustainability were particularly challenging for countries that were the first to introduce a rotavirus vaccine.
在拉丁美洲和加勒比地区，轮状病毒每年导致约1.5万人死亡、7.5万人住院、200万人次门诊就诊以及1000万例轮状病毒腹泻病例。有两种安全有效的疫苗可用于预防严重疾病。迄今为止，拉丁美洲的七个国家（巴西、厄瓜多尔、萨尔瓦多、巴拿马、墨西哥、尼加拉瓜和委内瑞拉）已引入该疫苗。为成功引入轮状病毒疫苗，汲取的经验教训再次强调，各国迫切需要制定精确计划，以确保疫苗引入在技术、规划和财政方面的可持续性。在这些经验教训中，对于率先引入轮状病毒疫苗的国家而言，规划可行性和财政可持续性尤其具有挑战性。
